Ingrid Kromann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ingrid Kromann has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Anna Särnefält
Manufacturing & Supply Chain, Coalition for Epidemic Preparedness Innovations, Askekroken 11, 0277 Oslo, Norway
2 shared publications Adriëtte W. de Visser
Leiden University Medical Center (LUMC), Department of Infectious Diseases, Leiden, The Netherlands
1 shared publication- Alessandro Lazdins
CEPI
1 shared publication Andrew Graves
Aeras, Rockville, MD, USA
1 shared publication- Antonio Guzzi
CEPI, UK
1 shared publication Birgit Thierry-Carstensen
Statens Serum Institut, Department of Vaccine Development, Artillerivej 5, Copenhagen 2300s, Denmark
1 shared publication
Latest Publications
- 13 September 2026
- Published by Springer Nature
- p. 1-16
Rapid Vaccine Development in Pre-pandemic Preparedness: Platform Analytics, Regulatory Readiness, and Digital Innovation
- 13 September 2026
- Published by Springer Nature
- p. 1-16
Rapid Vaccine Development in Pre-pandemic Preparedness: Platform Analytics, Regulatory Readiness, and Digital Innovation
- 25 July 2024
- Published by Parenteral Drug Association, Inc. in PDA Journal of Pharmaceutical Science and Technology
- Vol. 78 (5) , 613-623
A Strategic Guide to Improve and De-Risk Vaccine Development: CEPI’s CMC Framework
The Coalition for Epidemic Preparedness Innovations (CEPI) has developed a robust CMC (Chemistry, Manufacturing, and Controls) Framework to enhance the likelihood of successful vaccine development. This Framework serves as a comprehensive guide, aiding developers in building effective strategies to overcome the challenges posed by the different phases of vaccine development, including the ones often referred to as the "valleys of death". The Framework lists stage-appropriate deliverables, categorized and refined, spanning five key areas: manufacturing process, formulation and stability, analytics, supply chain, and compliance. By emphasizing the critical aspects of CMC development, CEPI9s objective is to expedite the progression of vaccine candidates from research to deployment, reducing delays, mitigating risks, and optimizing the overall development process, all while upholding uncompromising quality standards, ultimately increasing the probability of success.
- 25 July 2024
- Published by Parenteral Drug Association, Inc. in PDA Journal of Pharmaceutical Science and Technology
- Vol. 78 (5) , 613-623
A Strategic Guide to Improve and De-Risk Vaccine Development: CEPI’s CMC Framework
The Coalition for Epidemic Preparedness Innovations (CEPI) has developed a robust CMC (Chemistry, Manufacturing, and Controls) Framework to enhance the likelihood of successful vaccine development. This Framework serves as a comprehensive guide, aiding developers in building effective strategies to overcome the challenges posed by the different phases of vaccine development, including the ones often referred to as the "valleys of death". The Framework lists stage-appropriate deliverables, categorized and refined, spanning five key areas: manufacturing process, formulation and stability, analytics, supply chain, and compliance. By emphasizing the critical aspects of CMC development, CEPI9s objective is to expedite the progression of vaccine candidates from research to deployment, reducing delays, mitigating risks, and optimizing the overall development process, all while upholding uncompromising quality standards, ultimately increasing the probability of success.